Background: Malaria still becomes a major health problem in Indonesia, especially in the eastern part of Indonesia. The occurrence of Plasmodium resistance against antimalarial medications increases the difficulty of malaria wipe-out effort. As regard with such a great potential Sargassum production that Indonesia possesses, it is very likely to develop Sargassum as adjuvant therapy to prevent and even to stop the resistance.
Aim: This research aims to develop adjuvant therapy of Sargassum extract to avoid the resistance of malaria therapy on the SGPT level.
Method: There were 24 white rats (Rattus norvegicus) that had been infected by Plasmodium berghei and were given dihydroartemisinin-piperaquin (DHA-PPQ) therapy as antimalarial therapy at the dose of 3mg/KgBW for three consecutive days. The rats were later divided into three groups. Group 1 received only (DHA-PPQ), group 2 received Sargassum duplicatum extract as adjuvant therapy at Â the dose of 100 mg/KgBW for ten consecutive days. Group 3 also received Sargassum duplicatum extract as adjuvant therapy but the dose was at 300 mg/KgBW for ten consecutive days.
Result: SGPT level decreased more significantly in groups in which the rats received dihydroartemisinin-piperaquine and 100 mg/kgBW Sargassum extract as adjuvant therapy and on the other hand only received Sargassum extract at the dose of 300 mg/kgBW. After ten days of therapy the blood SGPT level was examined from all rats. The data were analyzed using one-way ANOVA test.
Conclusion: Sargassum duplicatum (100 mg/kgBW) showed a more significant decrease of SGPT level in Rattus norvegicus (Wistar strain) inoculated by Plasmodium berghei as against those in the dose 300 mg/kgBW.Â